Sirona Biochem, a biotechnology company, has announced that SBM-TFC-039, significantly and rapidly reduced the blood glucose level in obese diabetic rats (Zucker).
In an acute dosing study, six hours after treatment, the blood glucose level of obese diabetic rats was reduced to the level of control lean rats.
A strong correlation between the decrease in blood glucose level (0 to 6 hours post treatment) and the excretion of urinary glucose, is observed.
A study in normal rats also confirmed that SBM-TFC-039 triggered elimination of glucose through the urine (glycosuria) in a dose dependent manner.
SBM-TFC-039 also reduced blood glucose excursions following a glucose challenge by 34 percent compared to an untreated group, the company said.